Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Carlos Salama, Jian Han, Linda Yau, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 1, pp. 20-30
Open Access | Times Cited: 1182

Showing 1-25 of 1182 citing articles:

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Anthony Gordon, Paul Mouncey, Farah Al-Beidh, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 16, pp. 1491-1502
Open Access | Times Cited: 1755
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10285, pp. 1637-1645
Open Access | Times Cited: 1017
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Ewan C. Goligher, Charlotte Bradbury, Bryan J. McVerry, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 9, pp. 777-789
Open Access | Times Cited: 850
Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 802
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma Morris, Sattva S. Neelapu, Theodoros Giavridis, et al.
Nature reviews. Immunology (2021) Vol. 22, Iss. 2, pp. 85-96
Open Access | Times Cited: 629
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Peré Domingo, Isabel Mur, Gràcia Mateo, et al.
JAMA (2021) Vol. 326, Iss. 6, pp. 499-499
Open Access | Times Cited: 607
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 605-612
Open Access | Times Cited: 534
The signal pathways and treatment of cytokine storm in COVID-19
Lan Yang, Xueru Xie, Zikun Tu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 509
Innate immunity: the first line of defense against SARS-CoV-2
Michael Diamond, Thirumala‐Devi Kanneganti
Nature Immunology (2022) Vol. 23, Iss. 2, pp. 165-176
Open Access | Times Cited: 508
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou, Garyphallia Poulakou, Haralampos Milionis, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1752-1760
Open Access | Times Cited: 464
The first 12 months of COVID-19: a timeline of immunological insights
Thiago de Amorim Carvalho, Florian Krammer, Akiko Iwasaki
Nature reviews. Immunology (2021) Vol. 21, Iss. 4, pp. 245-256
Open Access | Times Cited: 425
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Patrícia O. Guimarães, Daniel Quirk, Remo Furtado, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 5, pp. 406-415
Open Access | Times Cited: 409
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1382-1392
Open Access | Times Cited: 405
Severe covid-19 pneumonia: pathogenesis and clinical management
A. Attaway, R.G. Scheraga, Adarsh Bhimraj, et al.
BMJ (2021), pp. n436-n436
Open Access | Times Cited: 378
COVID-19 and Cardiovascular Disease
Mina K. Chung, David A. Zidar, Michael R. Bristow, et al.
Circulation Research (2021) Vol. 128, Iss. 8, pp. 1214-1236
Open Access | Times Cited: 351
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
Kelvin Kai‐Wang To, Siddharth Sridhar, Kelvin Hei‐Yeung Chiu, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 507-535
Open Access | Times Cited: 304
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Peter Horby, Guilherme Pessoa-Amorim, Leon Peto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 303
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2
Meng Guo, Wanyin Tao, Richard A. Flavell, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 4, pp. 269-283
Open Access | Times Cited: 296
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Michael J. Peluso, Scott Lu, Alex Tang, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. 11, pp. 1839-1848
Open Access | Times Cited: 270
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Jean‐Claude Tardif, Nadia Bouabdallaoui, Philippe L. L’Allier, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 8, pp. 924-932
Open Access | Times Cited: 259
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
François-Xavier Lescure, Hitoshi Honda, Robert Fowler, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 5, pp. 522-532
Open Access | Times Cited: 231
Pathogenesis and treatment of cytokine storm in COVID-19
Mehmet Soy, Gökhan Keser, Pamir Atagündüz
TURKISH JOURNAL OF BIOLOGY (2021) Vol. 45, Iss. SI-1, pp. 372-389
Open Access | Times Cited: 229
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Sujin Kang, Tadamitsu Kishimoto
Experimental & Molecular Medicine (2021) Vol. 53, Iss. 7, pp. 1116-1123
Open Access | Times Cited: 219
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 9, pp. 1137-1146
Open Access | Times Cited: 215
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial
Arvinder S. Soin, Kuldeep Kumar, Narendra S. Choudhary, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 5, pp. 511-521
Open Access | Times Cited: 212
Page 1 - Next Page

Scroll to top